Aegle Therapeutics
Aegle Therapeutics is a clinical-stage developer of regenerative, immunomodulatory, and anti-inflammatory therapies using extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs). They focus on treating rare and severe diseases such as dystrophic epidermolysis bullosa (DEB) with their innovative EV platform technology, which has the potential to address a wide range of therapeutic indications. Their lead product, AGLE-102™, is a composite of EVs designed to promote tissue regeneration, reduce scarring, and improve healing in conditions like DEB.
Industries
Nr. of Employees
small (1-50)
Aegle Therapeutics
400 TradeCenter, Suite 5900, Woburn, MA 01801
Products
MSC-derived extracellular vesicle composite (AGLE-102)
A clinical-stage composite of bone marrow MSC-derived extracellular vesicles intended to deliver therapeutic proteins and nucleic acids to promote tissue regeneration and modulate inflammation in dermatological and wound-healing indications.
MSC-derived extracellular vesicle composite (AGLE-102)
A clinical-stage composite of bone marrow MSC-derived extracellular vesicles intended to deliver therapeutic proteins and nucleic acids to promote tissue regeneration and modulate inflammation in dermatological and wound-healing indications.
Services
Execution of early-phase clinical trials for EV-based therapeutics in rare dermatological and burn indications.
Preclinical efficacy and safety studies in wound and burn models to support IND-enabling data packages.
Manufacturing process for producing clinical-grade allogeneic bone marrow MSC-derived EV composites.
Execution of early-phase clinical trials for EV-based therapeutics in rare dermatological and burn indications.
Preclinical efficacy and safety studies in wound and burn models to support IND-enabling data packages.
Manufacturing process for producing clinical-grade allogeneic bone marrow MSC-derived EV composites.
Expertise Areas
- Extracellular vesicle therapeutics
- Regenerative medicine and wound healing
- Dermatology for rare genetic skin diseases (DEB/EB)
- Preclinical animal model development (porcine and rodent wound models)
Key Technologies
- MSC-derived extracellular vesicles (EVs)
- EV harvesting / isolation technology
- Proteomics for EV characterization
- mRNA and protein delivery via vesicles